• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
    • Editorial Board
    • Contact
  • Issues
    • Current Issue
    • Issue Archives
  • Multimedia
  • Editor's Update
  • Advertise
  • Reprints
  • Authors & Reviewers
    • Author Instructions
    • Submission Portal
    • Reviewers

Search

Controversial MS Treatment Lessens Fatigue, Research at ISET 2011 Shows

MIAMI BEACH, Fla.--(BUSINESS WIRE)--Multiple sclerosis (MS) patients may get some relief from severe fatigue from an experimental procedure to open blocked blood vessels in the chest and neck, suggests preliminary Stanford University research being presented at the 23rd annual International Symposium on Endovascular Therapy (ISET).

“If a person has MS and has a blood vessel obstruction, and if it’s removed, we will look at whether we can we demonstrate objectively that there is improvement in blood flow”

A year after doctors used either angioplasty or stents to open blocked veins of 30 MS patients, they suffered about half the fatigue, on average, than they had before the treatment, according to data being presented by Michael Dake, M.D., Thelma and Henry Doelger Professor in the Department of Cardiovascular Surgery at Stanford University School of Medicine in Stanford, Calif. Patients with the most common type of MS – relapsing-remitting – benefitted most.

Treatment for chronic cerebrospinal venous insufficiency (CCSVI) is controversial, with some doctors doubting the existence of the condition. Stanford and the Baptist Cardiac & Vascular Institute in Miami, plan to begin a trial in 2011 to assess the condition and treatment with angioplasty. “If a person has MS and has a blood vessel obstruction, and if it’s removed, we will look at whether we can we demonstrate objectively that there is improvement in blood flow,” Dr. Dake said.

The ISET meeting will feature several presentations on CCSVI. Among the featured speakers are Paolo Zamboni, M.D. of the University of Ferrara, Italy, a vascular surgeon who first proposed and is now testing the theory. Also speaking: patient advocates, skeptics, U.S. and Canadian doctors who provide the therapy, and James F. Benenati, M.D., president of the Society of Interventional Radiology.

About 400,000 Americans are affected by MS, which can be extremely debilitating, causing problems ranging from numbness and blurred vision to extreme fatigue and paralysis. The symptoms can come and go or become progressively worse.

Dr. Zamboni theorizes that abnormal blood flow can damage the nervous system and lead to MS. He reported initial results in 2009, suggesting the existence of CCSVI and that endovascular treatment relieved some MS symptoms and improved quality of life in certain MS patients. No U.S. studies have been published.

For more information, visit www.ISET.org.

Copies of ISET 2011 news releases are available online at www.ISETnews.org

Bookmark/Search this post with
  • Digg
  • LinkedIn
  • Reddit
  • Facebook Like
  • Google Plus One
  • Linkedin Share Button
  • Tweet Widget
image description image description


				
  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Kimberly Sutkowski, Classified Sales Representative
    (800) 237-7285, ext. 205

Vascular Access: The VDM Clinician Blog

Anticoagulant Treatment of DVT and Preventing DVT-PE Made Easier

Frank J Criado MD FACS FSVM

Retrograde Crossing: When the Front Door Is Locked, Look for Another Way In!

Ajay U. Mhatre MD

Collecting More Data for Vascular Patients

Lawrence A. Garcia MD

A Road Less Traveled: Access in the Right Brachial Artery

Ajay U. Mhatre MD

Endovascular Options for Complex Abdominal Aortic Aneurysms

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT
more »

Vascular Newswire

  • Elixir Medical Receives CE Mark Approval for the Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
    Wed, 05/15/13 - 10:12am
  • Reverse Medical Corporation Announces CE Mark and Initial Clinical Experience with the MVP Micro Vascular Plug for Peripheral Embolization
    Wed, 05/15/13 - 8:55am
  • St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
    Wed, 05/15/13 - 8:52am
  • Decades of Improving Cholesterol Levels Abruptly Ended in 2008, PLOS ONE Study Finds
    Tue, 05/14/13 - 10:02am
more »

Clinical Events Calendar

  • New Frontiers in Endovascular Therapy
    Fri, 05/17/2013 - Sat, 05/18/2013
    Jacksonville, FL, United States
  • EuroPCR 2013
    Tue, 05/21/2013 - Fri, 05/24/2013
    Paris, France
  • European Society for Vascular Surgery European Vascular Trauma Workshop
    Mon, 05/27/2013 - Tue, 05/28/2013
    Sweden
more »

Poll

Drug-eluting balloons will have a major role in lower-extremity revascularization in the future.:
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2013 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2013 HMP Communications